Palonosetron exhibits higher total control rate compared to first‑generation serotonin antagonists and improves appetite in delayed‑phase chemotherapy‑induced nausea and vomiting

Ueda,Hiroki; Shimono,Chigusa; Nishimura,Tomoyasu; Shimamoto,Megumi; Yamaue,Hiroki

doi:10.3892/mco.2014.263

Palonosetron exhibits higher total control rate compared to first‑generation serotonin antagonists and improves appetite in delayed‑phase chemotherapy‑induced nausea and vomiting

Authors:
- Hiroki Ueda
- Chigusa Shimono
- Tomoyasu Nishimura
- Megumi Shimamoto
- Hiroki Yamaue
View Affiliations

Affiliations: Department of Chemotherapy, Oncology Center, School of Medicine, Wakayama Medical University, Wakayama, Wakayama, Japan, Ambulatory Therapy Center, Wakayama Medical University, School of Medicine, Wakayama, Wakayama, Japan, Ambulatory Therapy Center, School of Medicine, Wakayama Medical University, Wakayama, Wakayama, Japan
Published online on: February 20, 2014 https://doi.org/10.3892/mco.2014.263
Pages: 375-379

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to ensure the continuity of chemotherapy, it is crucial to provide appropriate supportive care to prevent chemotherapy‑induced nausea and vomiting (CINV). The frequency of CINV is greatly affected by the type and combination of chemotherapy employed, which requires further investigation. With the use of patient diaries, a prospective study on the efficacy of antiemetic regimens for nausea and vomiting was conducted in 103 patients receiving highly or moderately emetogenic chemotherapy in the Ambulatory Therapy Center of our institution between August, 2010 and March, 2011. In this study, the efficacy of palonosetron in the delayed phase was affirmed. on days 4 and 5, in particular, palonosetron exhibited a significantly higher efficacy compared to that of other conventional serotonin (5‑HT3) receptor antagonists (5‑HT3RAs). When the effects of chemotherapy on food intake were assessed by switching granisetron to palonosetron, an improvement in appetite was observed in one‑quarter of the cases in the delayed phase. In addition, palonosetron has not been associated with any severe adverse drug reactions. It was therefore suggested that the use of palonosetron be recommended as a 5‑HT3RA. In conclusion, our data suggested that palonosetron is effective and may be used as a 5‑HT3RA, since it is crucial that we take adequate measures against CINV in order to maintain the patients' quality of life and to develop antiemetic regimens that ensure the continuity of chemotherapy without dose reduction.

View Figures

View References

1.	Neymark N and Crott R: Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer. 13:812–818. 2005. View Article : Google Scholar : PubMed/NCBI
2.	American Society of Clinical Oncology; Kris Mg, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
3.	National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology. Available at:https://www.nccn.org. Accessed August 10, 2013.
4.	Rolia F, Herrstedt J, Aapro M, et al: ESMO/MASCC Guidelines Working Group: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 21:v232–v243. 2010. View Article : Google Scholar
5.	Japan Society of Clinical Oncology: Guidelines for antiemetics in Oncology 2010. 1st edition. Japan: Kanehara Publishing Company Ltd.; Tokyo, Japan:
6.	Tavorath R and Hesketh PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs. 52:639–648. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Hesket PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med. 358:2482–2494. 2008. View Article : Google Scholar : PubMed/NCBI
8.	del Giglio A, Soares HP, Capparoz C and Castro PC: Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer. 89:2301–2308. 2000.PubMed/NCBI
9.	Geling O and Eichler HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 23:1289–1294. 2005. View Article : Google Scholar
10.	Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 23:2822–2830. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Saito M, Aogi K, Sekine K, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 10:115–124. 2009. View Article : Google Scholar
12.	Börjeson S, Hursti TJ, Peterson C, et al: Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 20:260–266. 1997.PubMed/NCBI
13.	Del Favero A, Roila F, Basurto C, et al: Assessment of nausea. Eur J Clin Pharmacol. 38:115–120. 1990.
14.	Maemondo M, Masuda N, Sekine I, et al: A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol. 20:1860–1866. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Eisenberg P, Figueroa-Vadillo J, Zamora R, et al 99-04 Palonosetron Study Group: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist. Cancer. 98:2473–2482. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Ho CM, Wu HL, Ho ST and Wang JJ: Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk. Acta Anaesthesiol Taiwan. 49:100–104. 2011. View Article : Google Scholar : PubMed/NCBI
17.	No authors listed: Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol. 16:2937–2942. 1998.PubMed/NCBI
18.	Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 18:233–240. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Tonato M, Clark-Snow RA, Osoba D, et al: Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer. 13:109–111. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 332:1–5. 1995. View Article : Google Scholar : PubMed/NCBI
21.	Roila F, Hesketh PJ, Herrstedt J, et al: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol. 17:20–28. 2006.PubMed/NCBI
22.	Tan L, Liu J, Liu X, et al: Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 23:1312009. View Article : Google Scholar : PubMed/NCBI
23.	Takeda H, Sadakane C, Hattori T, et al: Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT₂ receptor antagonism. Gastroenterology. 134:2004–2013. 2008. View Article : Google Scholar : PubMed/NCBI